Use of proton pump inhibitors and risk of osteoporosis-related fractures. - Wikidata - awgldk - TriplyDB

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

http://www.wikidata.org/entity/Q36803505

about

Overutilization of proton-pump inhibitors: what the clinician needs to know Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Chronic proton pump inihibitor therapy and calcium metabolism Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects.Perils and pitfalls of long-term effects of proton pump inhibitors.A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.Long-Term Alendronate Use Not without Consequences?Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.Decreased bone mineral density and reduced bone quality in H(+) /K(+) ATPase beta-subunit deficient mice.Dietary guideline adherence for gastroesophageal reflux disease Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspective Risk of fracture and pneumonia from acid suppressive drugs.Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium Adverse effects of long-term proton pump inhibitor therapy.Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease Hip fracture risk in patients with a diagnosis of pernicious anemia.Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation.Medication-induced osteoporosis: screening and treatment strategies Three-year results of a multicenter prospective study of transoral incisionless fundoplication.Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study Update on medications with adverse skeletal effects The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.Do proton pump inhibitors decrease calcium absorption?Association of peptic ulcer disease and pulmonary disease with risk of periprosthetic fracture after primary total knee arthroplasty.Pantoprazole decreases cell viability and function of human osteoclasts in vitro Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone.Acid-suppressive medications and risk of fracture: an updated meta-analysis.A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study Current trends in the management of gastroesophageal reflux disease: a review.Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement.Acute oxalate nephropathy associated with orlistat.

P2860

Q24634086-3D6E8847-74F3-41BC-A4BD-3DDB89292C66 Q26998249-E60728C4-1C05-49B0-AAF4-D8D342513346 Q27016636-BB1CEDD3-34FE-424E-BE32-D207BAB14A24 Q30448567-3A01E7CA-2EFC-40A4-B82C-2F33FA698F12 Q33409626-021ABE06-1DEF-4F10-ADED-CF748648B3A2 Q33441225-A1807BBD-8C0C-47D8-A7B0-BC1589AECE34 Q33611577-8C494A32-3DC6-4631-BE92-8065FF2A0A2A Q33633821-F8926DBF-D716-412C-B40A-9A9CDA252AF4 Q33832012-E07BD47E-E557-4A82-959C-23862923FB8D Q33893627-44DC031C-3B4B-44EE-A2B3-999D11ADFCBD Q33949498-6422B694-4B5D-448F-9B96-1E1DE9EA716D Q33987564-64943544-B345-4A32-89CA-C0A7C208AB1C Q34007127-6EC62372-536C-4EE2-BDFE-CC2990652DCA Q34070081-8539F4E7-111C-4AF3-BCBC-B4FF1366C444 Q34074981-FA41F6F2-291C-45F4-B83C-B65AC01057FC Q34092977-CBACCE3E-DC68-49F1-B805-52780FB9C887 Q34140914-B3D26F6D-0668-4659-85CC-C198A834075A Q34167899-39D3DDF1-BD83-4145-8827-F8532E9F05E0 Q34186827-3BD09A9A-13E7-4DBE-8F85-F1084F5FFFB0 Q34194502-05FA7766-2443-413F-8BAA-28A8622A9CEB Q34196326-F0012A48-E289-4E53-B8F2-A09D426D965C Q34268703-E4F382FE-C169-4069-91E6-97FDA3923836 Q34389358-16BF06CF-F119-44BC-8DEF-5B59502D95E4 Q34411526-5F70EC77-3C01-4F1C-9784-63BE56DEBBDE Q34554705-048267B8-7B9A-4133-A3DD-84005E8ED916 Q34557174-CD4E20C6-F723-421B-9D83-F7A5B07A11ED Q34748485-320588C5-B42D-47C0-B183-C9BA2F295D05 Q35052602-307F8637-A8EB-4FA1-B0CA-DB8573DC84BC Q35229828-17D00B2D-4C2D-4543-9A84-9D7295786830 Q35243751-D7F3DCA6-2697-4412-A118-494CBD412B6F Q35271665-CF7458CC-BAA5-4A5F-83A0-68EFFD4F34B6 Q35504164-0425C6C1-9861-4715-B53E-432BE6DF38A0 Q35719101-3765AA68-BBBD-4EB4-8AA7-228695AB2EAC Q35901581-2D0958A9-4BDE-4D4D-99AB-A4BBCA9A1980 Q35959430-A6CA4EE4-D09B-4D29-9397-D3658137F0E4 Q36037123-00343936-5A7F-40CC-BB23-BFAD091F5AB5 Q36107247-9EBE1A7E-8025-4F64-9624-3EE5DC0F0A39 Q36146084-E792C0EE-27CA-4B9A-869F-216EF741C064 Q36188966-EEB37921-1435-4EAF-B3D3-773D99FDA5C8 Q36835310-844DD788-D049-4E28-94A5-2D41BA7133E9

P2860

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

http://www.wikidata.org/entity/Q36803505

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@ast

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@en

type

label

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@ast

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@en

prefLabel

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@ast

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@en

P1433

Q36803505-7422E11E-3682-4B24-8868-FABF6E20E298

P1476

Q36803505-98BF3E41-2881-49E7-89DC-E490CD1835F6

P2093

Q36803505-852232C4-1198-4B10-B067-6D621A0096F2

Q36803505-9093712E-0004-4AA2-BEA9-2F97A31667E2

Q36803505-C8290173-0A21-4951-99CF-530002CDEC0A

Q36803505-E0FDE063-7AFD-4280-88F1-8C1E39BAA05C

Q36803505-EBB12DFE-5DB5-4E2E-9E96-A25CD3DCE476

Q36803505-F7DA2CEB-6956-4AB6-B1E8-CDEA9ECF0082

P2860

Q36803505-04F43E52-A348-4B84-B145-6B1CB22A2FA8

Q36803505-15BD92FE-EC74-4AC1-9582-6F6BC887A8F0

Q36803505-189734F2-5273-4B7F-B23B-C1D96470EEDF

Q36803505-205F6AB1-778D-4D8A-88E2-E100D385F29C

Q36803505-22795306-33F1-497E-AAB6-895CF0769652

Q36803505-2BD0AEB5-8E55-4C07-8719-7393CA53294E

Q36803505-2BDA8E6E-6D8F-41F9-82FB-A8B155D51544

Q36803505-30FC5C65-3E5E-4B0C-A704-8973B85083BC

Q36803505-3AB8314B-C74A-4A89-B341-89758A525A44

Q36803505-466B9C45-2491-49C2-B289-CB5EF290F871

P304

Q36803505-73CB553B-743C-4F9B-BD30-9EF3B630CB63

P31

Q36803505-F302A5E5-DB49-421B-8DD2-3ECD54E9E9CA

P356

Q36803505-F2238EA9-937A-4059-AAE5-42368293AA84

P407

Q36803505-1900BD1C-F699-4EEB-BDA0-54C9F72CF9BB

P433

Q36803505-5B24BAD7-92C0-4CD0-A8B6-B9EED0CD3455

P478

Q36803505-4B00C617-4C48-4ED7-BCB8-D593199546F7

P577

Q36803505-8A627782-7ED4-4C5B-B35C-0A9F49EC0397

P5875

Q36803505-EC6BAE85-E903-47F6-9548-768D8E0316CB

P698

Q36803505-F1360425-BE65-4092-91DA-74C396856C67

P921

Q36803505-9B511E03-63BA-430F-8ED2-DAA0E4CF3CF0

P932

Q36803505-2F84008F-6E27-4471-97CA-79C95AC84973

P356

P1433

Canadian Medical Association Journal

P1476

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

@en

P2093

Colleen J Metge

http://www.w3.org/2001/XMLSchema#string

Heather J Prior

http://www.w3.org/2001/XMLSchema#string

Laura E Targownik

http://www.w3.org/2001/XMLSchema#string

Lisa M Lix

http://www.w3.org/2001/XMLSchema#string

Stella Leung

http://www.w3.org/2001/XMLSchema#string

William D Leslie

http://www.w3.org/2001/XMLSchema#string

P2860

Calcium supplementation on bone loss in postmenopausal women

Risedronate for the prevention and treatment of postmenopausal osteoporosis

Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin

Establishing a population data-based policy unit.

Concordance between use of proton pump inhibitors and prescribing guidelines.

Use of oral corticosteroids and risk of fractures.

Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes.

Current and projected rates of hip fracture in Canada.

Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.

P304

319-326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.071330

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23163801

http://www.w3.org/2001/XMLSchema#string

P698

18695179

http://www.w3.org/2001/XMLSchema#string

P921

P932

2492962

http://www.w3.org/2001/XMLSchema#string